news8 March 2023 | By Catherine Eckford (European Pharmaceutical Review)
One of the first oral PCSK9 inhibitors tested in clinical trials significantly reduced low-density lipoprotein (LDL) cholesterol levels in patients with high cholesterol and/or heart disease.